Rayvio_News_Filter
Nov 19, 9:02 PM
$CLDX 🏥
Celldex Therapeutics, Inc. reported topline Phase 2 results showing barzolvolimab did not meet key efficacy measures or its internal hurdle rate for continued development in atopic dermatitis.
Market-relevant event
0 replies